CN1289105C - Bone pain dispersing granular composition and its preparation method - Google Patents
Bone pain dispersing granular composition and its preparation method Download PDFInfo
- Publication number
- CN1289105C CN1289105C CN 200510011563 CN200510011563A CN1289105C CN 1289105 C CN1289105 C CN 1289105C CN 200510011563 CN200510011563 CN 200510011563 CN 200510011563 A CN200510011563 A CN 200510011563A CN 1289105 C CN1289105 C CN 1289105C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- sclerotin
- radix
- rhizoma
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 27
- 206010006002 Bone pain Diseases 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 53
- 206010041591 Spinal osteoarthritis Diseases 0.000 claims abstract description 25
- 208000036319 cervical spondylosis Diseases 0.000 claims abstract description 25
- 208000005801 spondylosis Diseases 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 241000218176 Corydalis Species 0.000 claims abstract description 11
- 108010048734 sclerotin Proteins 0.000 claims description 93
- 239000008187 granular material Substances 0.000 claims description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 230000000202 analgesic effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 16
- 239000000341 volatile oil Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 13
- 235000008216 herbs Nutrition 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 7
- 238000004821 distillation Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 241000219780 Pueraria Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 241001180876 Saposhnikovia Species 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 92
- 230000036407 pain Effects 0.000 description 92
- 241000700159 Rattus Species 0.000 description 70
- 230000000694 effects Effects 0.000 description 34
- 206010037779 Radiculopathy Diseases 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 25
- 210000005036 nerve Anatomy 0.000 description 24
- 230000037396 body weight Effects 0.000 description 23
- 210000004969 inflammatory cell Anatomy 0.000 description 23
- 206010030113 Oedema Diseases 0.000 description 21
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000017531 blood circulation Effects 0.000 description 20
- 230000008595 infiltration Effects 0.000 description 20
- 238000001764 infiltration Methods 0.000 description 20
- 238000004043 dyeing Methods 0.000 description 19
- 210000004126 nerve fiber Anatomy 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 206010020565 Hyperaemia Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 210000000278 spinal cord Anatomy 0.000 description 13
- 230000008961 swelling Effects 0.000 description 13
- 210000000274 microglia Anatomy 0.000 description 12
- 230000024883 vasodilation Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000000835 fiber Substances 0.000 description 11
- 231100000915 pathological change Toxicity 0.000 description 11
- 230000036285 pathological change Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010028570 Myelopathy Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010020880 Hypertrophy Diseases 0.000 description 7
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 229960002275 pentobarbital sodium Drugs 0.000 description 7
- 210000001032 spinal nerve Anatomy 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 238000012109 statistical procedure Methods 0.000 description 6
- 230000001629 suppression Effects 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010018691 Granuloma Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 230000018044 dehydration Effects 0.000 description 5
- 238000006297 dehydration reaction Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 108010011485 Aspartame Proteins 0.000 description 4
- 206010061728 Bone lesion Diseases 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 4
- 229960003438 aspartame Drugs 0.000 description 4
- 235000010357 aspartame Nutrition 0.000 description 4
- 239000000605 aspartame Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 150000002338 glycosides Chemical class 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 3
- 240000001624 Espostoa lanata Species 0.000 description 3
- 206010015719 Exsanguination Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000007906 compression Methods 0.000 description 3
- 230000006835 compression Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000033687 granuloma formation Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010061928 radiculitis Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010005963 Bone formation increased Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- -1 Dichlorodiphenyl Acetate Chemical compound 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010041611 Spine malformation Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000746998 Tragus Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000019669 cervical disc degenerative disease Diseases 0.000 description 1
- 210000004889 cervical nerve Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000034540 ligamentous ossification Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 208000005198 spinal stenosis Diseases 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a medical composition for relieving bone pain, which is prepared from the raw materials comprising the following crude medicines: 100 parts by weight of Radix Puerariae, 100 parts by weight of ledebouriella root, 100 parts by weight of dahurian angelica, 100 parts by weight of atractylodes rhizome, 100 parts by weight of Notopterygium incisium, 100 parts by weight of safflower, 100 parts by weight of Rhizoma Polygoni Cuspidati, 100 parts by weight of corydalis tuber and 100 parts by weight of Caulis Spatholobi. The medical composition of the present invention has favorable therapeutic effect on cervical spondylosis.
Description
Technical field
The present invention relates to Chinese medicine composition that is used for the treatment of cervical spondylosis and preparation method thereof.
Background technology
The treatment to cervical spondylosis both at home and abroad is divided into operation and non-operation two class therapies, and non-operative treatment claims the combined therapy of Chinese and Western medicine, and promptly no matter doctor trained in Western medicine, the traditional Chinese medical science all adopt means such as massage, physical therapy, medication, sealing, traction.
Cervical spondylosis is principal contradiction with the bone lesion: the initial pathological change of cervical spondylosis is degeneration of cervical intervertebral disc, because its degeneration, can make fibrous ring, vertebral pulp is prominent to cause that to the ligament below ligament separates together with between periosteum and vertebra, form ligament-intervertebral disc space, because of many tearing with blood with local blood capillary simultaneously forms the gap hematoma,, form prominent at last to canalis spinalis or anterior margin of vertebral body bony spur along with organization of hematoma and calcium deposition.
Because degeneration of intervertebral disc, also can cause its durable pressure and traction force to lower, thereby narrowing of intervertebral space correspondingly occur, zygapophysial joints dislocation or overlapping, intervertebral foramina diminishes up and down: stability reduces between adjacent vertebral bodies, occurs little joint, uncovertebral joint hyperosteogeny, ligamentous ossification etc. then.Long-term in addition chronic strain, wound, inflammation and deformity etc. all can be brought out and be increased the weight of to stimulate pressuring neural root and vertebral artery.
Above-mentioned these pathological changes all belong to the category of bone lesion, can make sx because of developmental spinal stenosis equally.Therefore, one of purpose of the present invention provides a kind of reparation bony structures, recovers the medicine of cervical vertebra function.
Cervical vertebra ache is the cardinal symptom of cervical spondylosis: cervical spondylosis develops into certain phase, all the local pain symptom can occur.Primary disease main clinical symptom has the pain at positions such as head, neck, arm, hands and shirtfront, and the property of the carrying out limbs sensation and the dyskinesia can be arranged, weight person can cause the limbs weakness, even gatism, paralysis, involve vertebral artery and sympathetic nerve and then dizziness can occur, nervous, corresponding clinical manifestation such as heart beating.The outstanding behaviours of cervical spondylosis clinical symptoms is neck, shoulder, waist and leg pain, numb limbs and tense tendons, headache and dizzy, Hiccough and deaf, blurring of vision etc.
Although the pathogenic factor of cervical spondylosis is various, the pathological process complexity, aging, chronic strain, wound such as body, congenital spinal canal stenosis, congenital cervical spine malformation, unsuitable motions etc. all are the pathogenic factorss that causes cervical spondylosis, and in daily life, bad living habit, work posture is improper, sleep position is not good enough, external force injury is the immediate cause that causes cervical spondylosis.This symptom of pain makes patient's deepest feelings through lysis all the time, the most painful.Thus, the treatment cervical spondylosis eases the pain, and eliminates symptom, and the life quality that improves the patient is a matter of utmost importance wherein, and this also is one of purpose of the present invention.
Reciprocal causation between bone lesion and the pain, bone lesion be because of, pain be fruit.Current clinical medicine studies show that: osteoarticular wound of spinal column and disease, and as fracture, dislocation, tuberculosis, osteomyelitis, tumor, rheumatism and rheumatoid etc.Exogenous neck waist pain; Disease in the canalis spinalis,, intraspinal tumor etc. outstanding as spinal canal stenosis, vertebra shoulder dish all can cause pain.Simultaneously, these pathological changes can cause partial soft tissue lesions again.In all pain, the pain of 80%-85% is caused by above-described four class diseases.So the treatment bone diseases not only can be alleviated the damage of surrounding soft tissue, more effectively alleviating pain.
Summary of the invention
The object of the present invention is to provide a kind of Chinese medicine sclerotin disappear the pain compositions, it has excellent curative to cervical spondylosis, and does not have toxic and side effects.
Another object of the present invention provides a kind of Chinese medicine sclerotin pain preparation of compositions method that disappears.
The invention provides a kind of sclerotin stopping analgesic compositions, it is the preparation of being made by the raw material of group raw medicinal herbs under comprising: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae and 100-400 weight portion Rhizoma Atractylodis.
According to a preferred embodiment of the invention, the invention provides a kind of sclerotin stopping analgesic compositions, it is the preparation of being made by the raw material of group raw medicinal herbs under comprising: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae, 100-400 weight portion Rhizoma Atractylodis, 100-400 weight Rhizoma Et Radix Notopterygii and 100-400 weight portion Caulis Spatholobi.
According to a preferred embodiment of the invention, the invention provides a kind of sclerotin stopping analgesic compositions, it is the preparation of being made by the raw material of group raw medicinal herbs under comprising: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae, 100-400 weight portion Rhizoma Atractylodis, 100-400 weight Rhizoma Et Radix Notopterygii, 100-400 weight portion Flos Carthami and 100-400 weight portion Rhizoma Polygoni Cuspidati.
According to a more preferred of the present invention, the invention provides a kind of sclerotin stopping analgesic compositions, it is the preparation of being made by the raw material of group raw medicinal herbs under comprising: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae, 100-400 weight portion Rhizoma Atractylodis, 100-400 weight Rhizoma Et Radix Notopterygii, 100-400 weight portion Flos Carthami, 100-400 weight portion Rhizoma Polygoni Cuspidati, 100-400 weight portion Rhizoma Corydalis and 100-400 weight portion Caulis Spatholobi.
According to a more preferred of the present invention, the invention provides a kind of sclerotin stopping analgesic compositions, it is the preparation of being made by the raw material of group raw medicinal herbs under comprising: 100-200 weight portion Radix Puerariae, 100-200 weight portion Radix Saposhnikoviae, the 100-200 weight portion Radix Angelicae Dahuricae, 100-200 weight portion Rhizoma Atractylodis, 100-200 weight Rhizoma Et Radix Notopterygii, 100-200 weight portion Flos Carthami, 100-200 weight portion Rhizoma Polygoni Cuspidati, 100-200 weight portion Rhizoma Corydalis and 100-200 weight portion Caulis Spatholobi.
According to a more preferred of the present invention, the invention provides a kind of sclerotin stopping analgesic compositions, it is the preparation of being made by the raw material of group raw medicinal herbs under comprising: 100 weight portion Radix Puerariaes, 100 weight portion Radix Saposhnikoviaes, the 100 weight portion Radixs Angelicae Dahuricae, 100 weight portion Rhizoma Atractylodis, 100 weight Rhizoma Et Radix Notopterygiis, 100 weight portion Flos Carthamis, 100 weight portion Rhizoma Polygoni Cuspidati, 100 weight portion Rhizoma Corydalis and 100 weight portion Caulis Spatholobis.
Preferably, sclerotin stopping analgesic compositions of the present invention is the form of granule.
The present invention also provides sclerotin stopping analgesic preparation of compositions method, comprises following steps:
1) Rhizoma Atractylodis and/or Radix Saposhnikoviae and/or Rhizoma Polygoni Cuspidati and/or the Radix Angelicae Dahuricae are added the water that 6-12 doubly measures, vapor distillation is collected volatile oil, uses β-CDBao He, obtains beta-CD inclusion;
2) with above-mentioned 1) in medicinal residues add water with Flos Carthami and/or Caulis Spatholobi and decoct, filter filtrate and above-mentioned 1) in medicinal liquid merge, concentrated;
3) Rhizoma Corydalis and/or Radix Puerariae and/or Rhizoma Et Radix Notopterygii add the alcohol reflux of the 60-80% that 6-8 doubly measures, filter, and concentrate;
4) merge 2) and 3) in the concentrated solution of acquisition, further be condensed into thick paste, drying under reduced pressure obtains fine powder, with 1) in the beta-CD inclusion of the volatile oil that obtains mix.
The method according to this invention further comprises the just step of medicine granulation.
The present invention also provides compositions of the present invention to be used for the treatment of purposes in the medicament of cervical spondylosis in preparation.
Pharmaceutical composition of the present invention has following function: the tired weight of forearm, pain, numbness, cervical region activity that expelling wind and removing dampness, blood stasis dispelling are stimulated the menstrual flow, are used for due to the resistance of the rheumatism stasis of blood are unfavorable, nose heave etc.Be applicable to the treatment cervical spondylosis.
Sclerotin of the present invention disappears the pain granule when prescription, combine with differentiation of tcm and modern medicine treatment based on differentiation of disease, both at the characteristics of disease, again at the symptom characteristic, dual intervention, merely according to modern medical theory or have essential differently merely according to medicine, the health product of the treatment cervical spondylosis of theory of Chinese medical science prescription development, be one of main characteristic of medicine of the present invention on the performance comprehensive therapeutic effect, this point and present market.
The sclerotin pain granule cervical spondylosis for the treatment of that disappears, main pin is at heresy invasion and attack, the disharmony between QI and blood of traditional Chinese medical science rheumatism, and spondylotic radiculopathy, spinal compression type cervical spondylosis that obstruction of collaterals by blood stasis, the obstructed cervical spondylosis basic pathogenesis that causes of passages through which vital energy circulates and doctor trained in Western medicine are thought all have excellent curative.Can be described as Chinese and Western and lay equal stress on, characteristic is outstanding.This makes this medicine at symptomatic treatment, to having other single verifications aspect disease treatment, the doing well,improving or disease being treated, the difference that perhaps has essence based on the other kinds product that improves symptom, this is we's a characteristic, also by the advantage place of product.
Sclerotin of the present invention disappear the pain granule be pure Chinese medicinal preparation, have no side effect, safe.
The prescription of traditional treatment cervical spondylosis is used some functions dispelling wind and clearing away cold, removing dampness mostly, and the medicine of activating blood circulation to dissipate blood stasis and dredge the collateral is formed, and the big multiaction of these medicines is strong, and what have also has certain toxic and side effects, and these clinically can not prolonged application, has influenced and has applied.In order to address this problem, many producers carry out treatment by oral administration of medicines external treatment combined treatment based on the exploitation external used medicine at present.Because the Transdermal absorption problem of external used medicine can not finely solve, though alleviated the generation of toxic and side effects and untoward reaction, the curative effect of medicine is also correspondingly had a greatly reduced quality.
Sclerotin disappears the pain granule in when research and development, and for fear of the problems referred to above, by selected medical material, reasonable compatibility, scientific composition, the strict process of preparing Chinese medicine selected when the best means such as technology, avoided its weak point again.This just makes this product have higher curative effect and clinical specific aim, has eliminated the toxic and side effects and the untoward reaction of medicine again.We's main constituent is Radix Puerariae, Radix Saposhnikoviae, Ramulus Cinnamomi, the Radix Angelicae Dahuricae, Rhizoma Atractylodis, Flos Carthami, Rhizoma Et Radix Notopterygii, Rhizoma Corydalis, Caulis Spatholobi, pure Chinese medicinal preparation, above clinical drug is used thousand, has no side effect and the report of untoward reaction, and these have increased this security of products.
Acute toxicity testing shows, sclerotin of the present invention disappears the pain granule with gastric infusion continuously in the dose of the tolerant Cmax of animal, maximum volume one day, maximum dosage-feeding is 240.0 gram crude drug/kilograms, be equivalent to 480.0 times of clinical medicine dose, the reaction of observation experiment animal after the administration, observed 7 days continuously, animal body death, form, function are found in the end, and activity etc. occur unusual.
On this basis, we have carried out long term toxicity test again, with sclerotin of the present invention disappear the pain granule by the dosage (50 times, 25 times, 12.5 times of clinical medicine dose that are equivalent to the people) of 25.0,12.5,6.25 gram crude drug/kilogram/days respectively to laboratory animal filling stomach, in 26 weeks of continuous irrigation stomach, convalescent period observed 1 month.Experimental result shows that this product does not have influence to the ordinary circumstance of laboratory animal.Removing male high dose group rat body weight increasess slowly; Administration administration mid-term, outside middle dosage group, low dose group Serum ALT obviously reduce, second day (26 week), convalescent period after administration mid-term (13 week), the drug withdrawal, the rat peripheral hemogram of surveying and multinomial biochemical indicator all in normal range, fluctuate, not influence of ponderal index to important organ, macroscopy does not change, and finds no because drug-induced tangible pathomorphology changes through histopathological examination yet.
Description of drawings
Fig. 1 is the photochrome of rat cervical spondylotic radiculopathy: HE dyeing 10 * 40 normal control group nerve fibers are not seen fracture and inflammatory cell infiltration.
Fig. 2 is the fractures of the photochrome of rat cervical spondylotic radiculopathy: HE dyeing 10 * 40 model control group nerve fibers, a large amount of inflammatory cell infiltrations.
Fig. 3 is the photochrome of rat cervical spondylotic radiculopathy: the accidental fracture of pain heavy dose of group nerve fiber that disappears of HE dyeing 10 * 40 sclerotin, inflammatory cell soaks the ravine and obviously alleviates.
Fig. 4 is the photochrome of rat cervical spondylotic radiculopathy: as seen dosage group nerve fiber ruptured during HE dyeing 10 * 40 sclerotin disappeared bitterly, and Mild edema and inflammatory cell soak the ravine.
Fig. 5 is the photochrome of rat cervical spondylotic radiculopathy: the pain small dose group nerve fiber fracture that disappears of HE dyeing 10 * 40 sclerotin, inflammatory cell soaks the ravine.
Fig. 6 is the photochrome of rat cervical spondylotic radiculopathy: Mallory dyeing 10 * 40 normal control group collagen fiber even dyeing, and structure is normal.
Fig. 7 is the photochrome of rat cervical spondylotic radiculopathy: the big and heavy strong positive that is of Mallory dyeing 10 * 40 model control group collagen fiber.
Fig. 8 is the photochrome of rat cervical spondylotic radiculopathy: Mallory dyeing 10 * 40 sclerotin heavy dose of group of the pain collagen fiber that disappear are the weak positive.
Fig. 9 is the photochrome of rat cervical spondylotic radiculopathy: dosage group collagen fiber were the weak positive during Mallory dyeing 10 * 40 sclerotin disappeared bitterly.
Figure 10 is the photochrome of rat cervical spondylotic radiculopathy: Mallory dyeing 10 * 4040 sclerotin pain small dose group collagen fiber that disappear are the weak positive.
Figure 11 is the photochrome of rat spinal cord compressing myelopathy: HE dyeing 10 * 40 normal control group neurocytes are not seen enlargement, are taken off sheath.
Figure 12 is the photochrome of rat spinal cord compressing myelopathy: the obvious swelling of HE dyeing 10 * 40 model control group neurocytes, take off sheath, microglia hypertrophy.
Figure 13 is the photochrome of rat spinal cord compressing myelopathy: HE dyeing 10 * 40 sclerotin disappear the swelling of the heavy dose of group of pain neurocyte, microglia, take off sheath and all obviously alleviate.
Figure 14 is the photochrome of rat spinal cord compressing myelopathy: HE dyeing 10 * 40 sclerotin disappear the swelling of dosage group neurocyte, microglia in the pain, take off sheath and all obviously alleviate.
Figure 15 is the photochrome of rat spinal cord compressing myelopathy: HE dyeing 10 * 40 sclerotin disappear the swelling of pain small dose group neurocyte, microglia, take off sheath and all have necessarily and alleviate.
The specific embodiment
Preparation embodiment 1
200g Rhizoma Atractylodis, 200g Radix Saposhnikoviae and the 200g Radix Angelicae Dahuricae are added 9 times of water gagings, and vapor distillation 6 hours is collected volatile oil, volatile oil is with β-CDBao He (oil: β-CD: water=1: 8: 80,60 ℃ of following enclose 1.0 hours), cold preservation 24 hours, filtration low humidity drying promptly gets beta-CD inclusion.Above-mentioned residual medicine dreg is added water to 9 times of amounts of Chinese crude drug, decoct together 3 times, filter, filtrate and above-mentioned medicinal liquid merging are concentrated into relative density 1.10-1.20 (50 ℃).The 200g Radix Puerariae adds 70% ethanol of 7 times of amounts, and reflux, extract, 3 times each 2 hours, filters.Merge ethanol liquid, reclaim ethanol and concentrated, concentrated solution and above-mentioned concentrated solution continue to be condensed into thick paste after merging, and drying under reduced pressure grinds into fine powder and volatile oil beta-CD inclusion and mixes.It is an amount of to add aspartame and dextrin, and mixing is granulated, drying, promptly.
Preparation embodiment 2
400g Rhizoma Atractylodis, 400g Radix Saposhnikoviae and the 100g Radix Angelicae Dahuricae are added 12 times of water gagings, and vapor distillation 4 hours is collected volatile oil, volatile oil is with β-CDBao He (oil: β-CD: water=1: 8: 80,60 ℃ of following enclose 1.0 hours), cold preservation 24 hours, filtration low humidity drying promptly gets beta-CD inclusion.Above-mentioned residual medicine dreg and 200g Caulis Spatholobi are added water to 12 times of amounts of Chinese crude drug, decoct together 3 times, filter, filtrate and above-mentioned medicinal liquid merging are concentrated into relative density 1.10-1.20 (50 ℃).100g Radix Puerariae and 200g Rhizoma Et Radix Notopterygii add 60% ethanol of 8 times of amounts, and reflux, extract, 4 times each 1.5 hours, filters.Merge ethanol liquid, reclaim ethanol and concentrated, concentrated solution and above-mentioned concentrated solution continue to be condensed into thick paste after merging, and drying under reduced pressure grinds into fine powder and volatile oil beta-CD inclusion and mixes.It is an amount of to add aspartame and dextrin, and mixing is granulated, drying, promptly.
Preparation embodiment 3
100g Rhizoma Atractylodis, 100g Radix Saposhnikoviae, the 400g Radix Angelicae Dahuricae and 200g Rhizoma Polygoni Cuspidati are added 6 times of water gagings, vapor distillation 8 hours, collect volatile oil, volatile oil β-CDBao He (oil: β-CD: water=1: 8: 80,60 ℃ of following enclose 1.0 hours), cold preservation 24 hours filters the low humidity drying, promptly gets beta-CD inclusion.Above-mentioned residual medicine dreg and 200g Flos Carthami are added water to 10 times of amounts of Chinese crude drug, decoct together 3 times, filter, filtrate and above-mentioned medicinal liquid merging are concentrated into relative density 1.10-1.20 (50 ℃).400g Radix Puerariae and 100g Rhizoma Et Radix Notopterygii add 80% ethanol of 6 times of amounts, and reflux, extract, 3 times each 2 hours, filters.Merge ethanol liquid, reclaim ethanol and concentrated, concentrated solution and above-mentioned concentrated solution continue to be condensed into thick paste after merging, and drying under reduced pressure grinds into fine powder and volatile oil beta-CD inclusion and mixes.It is an amount of to add aspartame and dextrin, and mixing is granulated, drying, promptly.
Preparation embodiment 4
100g Rhizoma Atractylodis, 100g Radix Saposhnikoviae, the 100g Radix Angelicae Dahuricae and 100g Rhizoma Polygoni Cuspidati are added 9 times of water gagings, vapor distillation 6 hours, collect volatile oil, volatile oil β-CDBao He (oil: β-CD: water=1: 8: 80,60 ℃ of following enclose 1.0 hours), cold preservation 24 hours filters the low humidity drying, promptly gets beta-CD inclusion.Above-mentioned residual medicine dreg and 100g Flos Carthami and 100g Caulis Spatholobi are added water to 11 times of amounts of Chinese crude drug, decoct together 3 times, filter, filtrate and above-mentioned medicinal liquid merging are concentrated into relative density 1.10-1.20 (50 ℃).100g Radix Puerariae, 100g Rhizoma Corydalis and 100g Rhizoma Et Radix Notopterygii add 70% ethanol of 7 times of amounts, and reflux, extract, 3 times each 2 hours, filters.Merge ethanol liquid, reclaim ethanol and concentrated, concentrated solution and above-mentioned concentrated solution continue to be condensed into thick paste after merging, and drying under reduced pressure grinds into fine powder and volatile oil beta-CD inclusion and mixes.It is an amount of to add aspartame and dextrin, and mixing is granulated, drying, promptly.
Effect embodiment
The dosage design sclerotin clinical consumption per day of pain granule people that disappears is the 30g crude drug, calculates by 60 kg body weight, and dosage is 0.5g crude drug/kg; In animals and human beings kg body weight ratio conversion, mice dosage is 10.8,5.4,2.7g crude drug/kg; Rat dosage is 5.4g, 2.7g, three dosage of 1.35g crude drug/kg.Middle dosage is equivalent to clinical equivalent dosage, and high dose is the twice of middle dosage, and low dose is 1/2 times of middle dosage.
Reagent Oleum Tiglii, Japan and light Co., Ltd. product, lot number DCCL 7737.Macromolecule right rotary glycoside, Sigma company product, D-5251, molecular weight are 580000.
Animal: CD-1 (ICR) mice; 18-22g, male and female half and half; The SD rat, 210-230g, Wistar rat 140-160g body weight, male, all mountain Beijing Vital River Experimental Animals Technology Co., Ltd. provides, and the animal quality certification number is SCXK (capital) 2002-0003.
Experiment medicine: the sclerotin that makes according to the method that prepare embodiment 4 granule bitterly that disappears
Laboratory animal occupancy permit: credit number: SYXK (capital) 2000-0048.The scope of application: barrier environment: Rodents.Effect duration: 2000 05 month 25 on 05 24th, 2005.
Instrument: SAKURA automatic dehydration machine: Japan produces: the Leite rotary microtome: Germany produces; SAKURA RSH-100 automatic staining machine: Japan produces; Optical microscope: Japanese Nikon: the automatic microphotograph of OLYMPUS BH-2 system; LG-R-80 series blood viscosity tester, Beijing Steellex Scientific Instrument Company produces.
Method and result
1. sclerotin disappears the pain granule to the therapeutical effect of rat cervical spondylosis
1.1 65 of rats are chosen in the influence of rat cervical spondylotic radiculopathy, except that normal control group (10), all the other rats are with 3% pentobarbital sodium 1ml/kg intraperitoneal injection of anesthesia, conventional preserved skin, sterilization, with the second dorsal vertebra spinous process is sign, neck 6 is the center, along spinous process longitudinal incision skin, the about 1.5cm of otch, strut separation musculi colli and spinous process both sides muscle with shears, expose spinous process and both sides vertebral plate, cut off neck 6 with eye scissors, the above vertebral plate of 7 one side transverse process exposes spinal cord in the canalis spinalis, peel off nerve and push spinal cord to a side low-necked 6 nerve rooies, the quantitative filter paper sheet that is soaked with formalin is applied on the nerve root of left side.Careful hemostasis, layer-by-layer suture muscle, skin.The sterile surgical position was observed 1 day in the cage, and the left side fore paw is held motionless person and is the modeling success.
50 model mouses are taken into account random packet by activity situation and body weight, gastric infusion, model group and blank group give the distilled water of equal volume, continuous 14 days, dissect in second day after the drug withdrawal.
Weigh once weekly during the administration, and observe the activities in rats situation.Calculate weight gain value with the t check, with x
2Calculate the activities in rats recovery situation.
Dissect fasting the previous day, press 1ml/kg pentobarbital sodium intraperitoneal injection of anesthesia with 3% pentobarbital sodium, ventral aorta blood sampling anticoagulant is measured whole blood viscosity with LG-R-80 series blood viscosity tester.(Dongzhimen hospital blood circulation promoting and blood stasis dispelling group is measured), the sacrificed by exsanguination rat is got the cervical region nerve and uses 10% formaldehyde fixed, ethanol dehydration, dimethylbenzene is transparent, waxdip embedding, section, HE and Mallory dyeing, pathological study.Observation index: adopt radiculitis and nerve fiber pathological changes comprehensively to judge, carry out statistical procedures with the t check.
The rat behavior standards of grading:
The normal heavy burden, the joint is agile, and pawl lands, and remembers 0 fen;
Left side pawl lands, and the articular instability rope is walked lamely, and can not normally bear a heavy burden, and remembers 1 fen;
Left side metacarpophalangeal joints song, the side palm lands, and walks lamely, and can not normally bear a heavy burden, and remembers 2 fens;
Left side wrist song, wrist lands, and is jumping and is walking lamely, and can not normally bear a heavy burden, and remembers 3 fens;
Left side elbow song, elbow lands, and can not stand, and remembers 4 fens.
The histopathology criterion
The nerve root blood vessel is not seen expansion, hyperemia, nerve fiber, and water breakthrough is not swollen, inflammatory cell infiltration, and structure is normal, and keeping the score is 0;
Nerve fiber Mild edema, a small amount of inflammatory cell infiltration, keeping the score is 1;
Nerve root vasodilation, the nerve fiber Mild edema, inflammatory cell infiltration, keeping the score is 2;
Nerve root vasodilation, hyperemia, the obvious edema of nerve fiber, a large amount of inflammatory cell infiltration, keeping the score is 3.
Nerve root vasodilation, hyperemia, the obvious edema of nerve fiber, fracture, a large amount of inflammatory cell infiltrations, keeping the score is 4.
Table 1 sclerotin disappears the pain granule to the influence of cervical spondylotic radiculopathy rat body weight
| Group | Dosage (g/kg) | Mus number (only) | Body weight before the medicine | Weight gain value behind the medicine (g) | |
| 1 week | 2 weeks | ||||
| Model control group | - | 10 | 235.3±4.6 | 28.1±5.8 | 62.2±9.9 |
| The normal control group | - | 10 | 234.3±5.6 | 43.0±5.6 * | 85.2±9.6 |
| Sclerotin disappear the pain granule | 10.8 | 10 | 233.5±6.6 | 36.5±8.7 * | 76.0±13.1 * |
| 5.4 | 10 | 232.1±7.5 | 35.4±7.1 * | 73.3±7.8 * | |
| 2.7 | 10 | 233.8±7.0 | 33.1±11.2 | 72.0±11.9 | |
With model control group:
*P＜0.01,
*P＜0.05
Table 1 is the result show, the model group rat body weight increases with the normal control group to be compared significantly slowly, and three dosage groups are compared the growth that all has in various degree with model group, and high, middle dosage group increases significantly.
Table 2 sclerotin disappears the pain granule to the influence of cervical spondylotic radiculopathy activities in rats situation
| Group | Dosage (g/kg) | Activity recovery rate (%) | Movable before the administration | Activities in rats situation after the administration (my god) | |
| 7 | 14 | ||||
| Model control group | - | 40 | 2.7±0.82 | 2.3±0.95 | 1.0±1.05 |
| Sclerotin disappear the pain granule | 5.4 | 90 * | 2.6±0.70 | 1.4±0.52 * | 0.1±0.32 * |
| 2.7 | 80 | 2.5±0.85 | 1.5±0.53 * | 0.3±0.67 * | |
| 1.35 | 70 | 2.6±0.70 | 1.8±0.63 | 0.4±0.70 | |
Compare with model control group
*P＜0.05
Table 2 is the result show, administration 14 days, and it is just normal that model group activities in rats obstacle 60% does not recover, sclerotin pain granule three the dosage groups that disappear all can be improved the activity of rat fore paw in various degree during the administration, high, middle dosage effect is obvious, and it is normal that 80-90% recovers, and the 10-20% moving obstacle obviously alleviates.
Table 3 result shows that model entangles the vasodilation of rat nerve root, hyperemia, the obvious edema of fiber, fracture, necrosis, a large amount of inflammatory cell infiltration (based on lymphocyte).The administration group all has improvement in various degree, and large and small dosage effect is (Fig. 1-10) obviously.
Brief summary cervical spondylotic radiculopathy rat body weight obviously descends, limitation of activity, the vasodilation of pathological observation nerve root, hyperemia, the obvious edema of fiber, fracture, necrosis, a large amount of inflammatory cell infiltration.Administration group body weight rises appreciably, and activity recovers substantially, and vasodilation, fiber edema, inflammatory cell infiltration etc. all obviously alleviate.
The influence that the pain granule changes rat cervical spondylotic radiculopathy histopathology that disappears of table 3 sclerotin
| Form | Dosage (g/kg) | Mus number (only) | The pathological changes integration |
| Model control group | - | 10 | 2.7±0.67 |
| Sclerotin disappear the pain granule | 5.4 | 10 | 1.8±0.79 * |
| 2.7 | 10 | 1.9±0.74 * | |
| 1.35 | 10 | 2.1±0.88 |
Compare with model control group
*P＜0.05
1.2 65 of rats are chosen in the influence to rat spinal cord compressing myelopathy, except that the normal matched group of positive pawl (10), all the other rats are with 3% pentobarbital sodium 1ml/kg intraperitoneal injection of anesthesia, conventional preserved skin, sterilization, with the second dorsal vertebra spinous process is sign, along spinous process longitudinal incision skin of neck, the about 1.5cm of otch, strut separation musculi colli and spinous process both sides muscle with shears, expose spinous process and both sides vertebral plate, cut off neck 4,5 ligamenta flava, expose intervertebral space, 2mm * 4mm * 1mm silica gel sheet (the root line is worn in the centre) is inserted canalis spinalis, with the linear system on the silica gel sheet nearby on the muscle with fixing silica gel sheet, layer-by-layer suture muscle, skin.The sterile surgical position was observed 2 days in the cage.
50 model mouses are pressed active state and body weight random packet, gastric infusion, model group and blank group give the distilled water of equal volume, continuous one month, dissect in second day after the drug withdrawal.Weigh weekly once during the administration, with weight gain value after the t check calculating administration.
Dissect fasting the previous day, press 1ml/kg pentobarbital sodium intraperitoneal injection of anesthesia with 3% pentobarbital sodium, ventral aorta blood sampling anticoagulant is measured whole blood viscosity with LG-R-80 series blood viscosity tester.(Dongzhimen hospital blood circulation promoting and blood stasis dispelling group is measured), the sacrificed by exsanguination rat is got cervical spinal cord 10% formaldehyde fixed, ethanol dehydration, dimethylbenzene is transparent, waxdip embedding, section, HE dyeing, pathological study.Observation index: adopt the spinal nerves cell, the denaturation degrees of microglia is comprehensively judged, carries out statistical procedures with the t check.
The histopathology criterion
The spinal nerves cell, microglia is not seen degeneration, and structure is normal, and keeping the score is 0;
Spinal nerves cell mild swelling, the slight hypertrophy of microglia, the note heart is divided into 1;
The swelling of spinal nerves cell moderate, microglia moderate hypertrophy, keeping the score is 2;
The spinal nerves cellular swelling is obvious, the microglia hypertrophy, and the sheath phenomenon appears taking off in neurocyte, and keeping the score is 3.
The spinal nerves cellular swelling is obvious, the microglia hypertrophy, and the partial nerve cell takes off sheath, and keeping the score is 4.
Table 4 sclerotin disappear the pain granule to the shadow of rat spinal cord compressing myelopathy body weight
| Group | Dosage (g/kg) | Weight gain value behind the medicine (g) | |||
| 1 week | 2 weeks | 3 weeks | 4 weeks | ||
| Model control group | - | 27.8±6.51 | 55.5±6.88 | 80.1±8.95 | 105.3±9.68 |
| The normal control group | - | 39.4±5.1 ** | 70.8±7.66 ** | 96.0±9.61 ** | 121.2±8.44 ** |
| Sclerotin disappear the pain granule | 5.4 | 34.6±6.22 * | 66.7±10.03 * | 91.8±9.92 * | 117.4±10.79 * |
| 2.7 | 35.2±6.92 | 67.5±11.36 * | 91.1±11.18 | 114.5±11.69 | |
| 1.35 | 32.5±8.60 | 62.9±11.92 | 89.8±11.88 | 111.7±13.70 | |
Compare with model group
*P＜0.05,
*P＜0.01
Table 4 is the result show, the model group rat body weight increases with the normal control group to be compared significantly slowly, and three dosage groups are compared with model group and increased comparatively fast, and high dose group increases obviously.
The influence of pain granule that disappear of table 5 sclerotin to the pathological change of rat spinal cord compressing myelopathy
| Form | Dosage (g/kg) | Mus number (only) | The pathological changes integration |
| Model control group | - | 10 | 2.6±0.70 |
| Sclerotin disappear the pain granule | 5.4 | 10 | 1.8±0.42 * |
| 2.7 | 10 | 1.9±0.57 * | |
| 1.35 | 10 | 2.0±0.47 * |
Compare with model control group,
*P＜0.05
Table 5 result shows, the obvious swelling of model group rat spinal cord neurocyte, and the partial nerve cell takes off sheath, a matter microglia hypertrophy, the little congestion of blood vessel, the administration group all has improvement in various degree, and high, middle dosage effect is (Figure 11-15) obviously.
2. the sclerotin pain granule antiinflammatory action that disappears
2.1. the mice that influences to mice auricular concha Oleum Tiglii inflammation is pressed the body weight random packet, matched group, sclerotin three the dosage groups of pain granule high, medium and low (10.8,5.4,2.7g/kg body weight) that disappear, every group 10, every day gastric infusion once, 0.2ml/10g body weight (matched group gives the distilled water of equal volume), continuous three days.Behind the last medicine 1 hour, only be applied to two sides before and after the left ear with 2% Oleum Tiglii 0.05ml/, auris dextra is contrast, cause scorching back 4 hours mice is put to death, cut two ears along the auricle baseline, sweep away auricle respectively at same position, on electronic balance, weigh with the rustless steel punching pin of diameter 6mm.Weight difference with left and right sides auricle is the swelling degree, calculates and respectively organizes swelling degree average, does the t check, the comparable group differences.
The table 6 sclerotin pain granule that disappears brings out the inhibitory action (X ± SD) of mouse ear edema to Oleum Tiglii
| Group | Dosage (g/mg) | Mus number (only) | Ear swelling value (mg) | Suppression ratio (%) |
| Matched group | - | 10 | 18.9±2.38 | |
| Sclerotin disappear the pain granule | 10.8 | 10 | 14.2±4.96 * | 24.9 |
| 5.4 | 10 | 14.0±5.44 * | 25.9 | |
| 2.7 | 10 | 15.5±4.50 | 18.0 |
Compare with matched group
*P＜0.05
Table 6 result as seen, the sclerotin mice ear that pain granule height, middle dosage cause Oleum Tiglii that disappears has stronger inhibitory action.
2.2 the swollen rat ether light anaesthesia that influences that forms is made abdominal incision under aseptic condition to rat granuloma, it is subcutaneous that the sterilization cotton balls of 20mg is implanted the both sides groin.Postoperative is divided into five groups at random, matched group, sclerotin three the dosage groups of pain granule high, medium and low (5.4,2.7,1.35g/kg body weight) that disappear, 10 every group.Performing the operation began administration the same day, once a day, the 1ml/100g body weight, continuous 7 days, peeled off and take out cotton balls granulation tissue with the rat sacrificed by decapitation half an hour behind the 8th day medicine.Weigh after 12 hours in 60 ℃ of baking oven inner dryings, deduct cotton balls weight, be the granuloma net weight, carry out statistical procedures with the t check, relatively granuloma has there was no significant difference between each group.
Table 7 sclerotin disappears the pain granule to the swollen outgrowth influence of rat granuloma (X ± SD)
| Group | Dosage (g/mg) | Number of animals (n) | Granulation dry weight (mg) | Suppression ratio (%) |
| Matched group | - | 10 | 54.75±15.12 | |
| Sclerotin disappear the pain granule | 5.4 | 10 | 38.15±16.75 ** | 30.3 |
| 2.7 | 10 | 41.35±17.33 ** | 24.5 | |
| 1.35 | 10 | 43.40±18.35 * | 20.7 |
Compare with matched group,
*P＜0.05
*P＜0.01
The result by table 7 as seen, the sclerotin pain granule institute amount of reagent that disappears all has obvious inhibitory action to cott on pellet-induced granuloma formation, high, middle dosage effect is remarkable.
Sclerotin disappear the pain particulate analgesic activity
3.1 Dichlorodiphenyl Acetate causes the influence of mice pain reaction and gets healthy mice, be divided into 5 groups at random by body weight, matched group, sclerotin disappear pain granule 10.8,5.4, three dosage groups of 2.7g crude drug/kg, every group 10, for three days on end, gastric infusion, 0.2ml/10g, after the last administration 1 hour, every Mus lumbar injection 0.6% acetum 0.2ml, record caused pain mouse writhing number of times in 15 minutes after 5 minutes.
Table 8 sclerotin disappears the pain granule to the analgesic activity of mice (X ± SD)
| Group | Dosage (g/mg) | Mus number (only) | Turn round body number (inferior) | Suppression ratio (%) |
| Matched group | - | 10 | 34.6±8.11 | |
| Sclerotin disappear the pain granule | 10.8 | 10 | 20.7±8.56 ** | 40.2 |
| 5.4 | 10 | 25.9±6.54 * | 25.1 | |
| 2.7 | 10 | 24.7±9.07 * | 28.6 |
Compare with matched group,
*P＜0.05
*P＜0.01
The result is visible 8 by table, and the sclerotin pain granule that disappears can significantly suppress the mouse writhing generation number that acetic acid causes, compares with matched group, and significant difference is arranged.
3.2. the influence that front foot subcutaneous injection formalin is caused the mice pain reaction is got the 18-22g healthy mice and is divided into 5 groups at random by body weight, every group 10, gastric infusion for three days on end, 0.2ml/10g the 3rd day, the formalin solution 20ul/ of the right front vola of mice subcutaneous injection 2% only caused inflammation, cause after the inflammation administration immediately 1 time, after 1 hour, mice is inserted in the 1000ml beaker, observe the foot reaction of mice.Add up with pain reaction classification integration.
Pain grade scale: lick, sting or trembled sufficient 3 minutes; Carry foot 2 minutes: touch the bottom surface but do not bear a heavy burden, walked lamely 1 fen during walking; The normal heavy burden walked about 0 minute freely.
The experimental result sclerotin pain granule institute amount of reagent that disappears can obviously reduce subcutaneous injection formalin and causes mice pain reaction integration, compares with matched group, and significant difference is arranged.(table 9).
The table 9 sclerotin pain granule that disappears causes the influence of mice pain reaction to subcutaneous injection formalin
| Group | Dosage (g/mg) | Mus number (only) | Pain response value (branch) | Suppression ratio (%) |
| Matched group | - | 10 | 2.2±0.79 | |
| Sclerotin disappear the pain granule | 10.8 | 10 | 1.0±0.67 ** | 54.55 |
| 5.4 | 10 | 1.1±0.74 ** | 50.00 | |
| 2.7 | 10 | 1.4±0.70 * | 36.36 |
Annotate: compare with matched group
*P＜0.05
*P＜0.01
Sclerotin disappear the pain the particulate effect of invigorating blood circulation
The pain granule sees that to the hemorheological test method that influences of rat cervical spondylotic radiculopathy 1.2 sclerotin disappear the pain granule to the influence of rat cervical spondylotic radiculopathy 4.1 sclerotin disappears.
Table 10 sclerotin disappears the pain granule to the influence of cervical spondylotic radiculopathy rat whole blood viscosity (X ± SD)
| Group | Dosage (g/kg) | Whole blood viscosity (shear rate 1/S) | |||
| 5 | 10 | 38 | 150 | ||
| Model control group | - | 18.0±1.96 | 13.1±1.27 | 8.3±0.65 | 6.2±0.42 |
| The normal control group | - | 13.2±1.76 ** | 9.8±1.17 ** | 6.4±0.64 ** | 4.9±0.43 * |
| Sclerotin disappear the pain granule | 5.4 | 15.4±1.58 ** | 11.2±1.05 ** | 7.1±0.60 ** | 5.4±0.45 ** |
| 2.7 | 17.7±2.76 | 12.8±1.85 | 8.0±1.01 | 5.9±0.68 | |
| 1.35 | 17.0±2.03 | 12.5±1.39 | 8.1±0.79 | 6.1±0.57 | |
Compare with model group
*P＜0.05,
*P＜0.01
Table 10 result as seen, the model control group whole blood viscosity is compared remarkable rising with the normal control group, all administration groups all have reduction in various degree, the sclerotin pain granule high dose group that disappears has the obvious suppression effect, can significantly reduce the whole blood viscosity.
The pain granule is divided into 5 groups to the microcirculatory influence of mice [9] mice at random by body weight 4.2 sclerotin disappears, continuous three days gastric infusions, and behind the last medicine 1 hour, 0.5% pentobarbital sodium 0.2ml/20g anaesthetized by 50mg/kg dosage lumbar injection.Cut off the mice tragus, be placed on the microscope carrier, select the identical venule of Mus ear same position flow velocity to observe, and blood flow rate before the record modeling.Caudal vein is injected 10% macromolecule right rotary glycoside 1mg/kg and is caused the circulatory disturbance model, observe and write down blood flow rate and flow restoration immediately to just often time, return to the normal time less than 0.5 minute by 0.5 minute, greater than 30 minutes by 30 minutes.Each group blood flow rate and recovery time are carried out statistical procedures with the t check.
The flow velocity criterion;
Linear flow: blood flow is fast, is smooth streak, and no granular sensation is decided to be 4;
Line grain stream: blood flow is very fast, is streak, and granular sensation is arranged slightly, is decided to be 3;
The grain linear flow: blood flow is slower, though be line continuously, obvious grain sense is arranged, and is decided to be 2;
The grain unhurried current: blood flow is the silt sample, and sluggish flow is decided to be 1 continuously;
Grain pendulum stream: blood flow is the silt shape, though flow forward, swing is decided to be 0.5;
Stagnate: blood flow is stagnated motionless, is decided to be 0.
Table 11 sclerotin disappears the pain granule to the microcirculatory influence of mice
| Group | Dosage (g/mg) | Mus number (only) | Blood flow rate | Recovery time | |
| Before making film | After making film | (branch) | |||
| Matched group | - | 10 | 3.8±0.42 | 0.90±0.46 | 21.5±4.25 |
| Sclerotin disappear the pain granule | 10.8 | 10 | 3.9±0.32 | 1.60±0.81 * | 15.5±5.93 * |
| 5.4 | 10 | 3.8±0.42 | 1.45±0.60 * | 15.7±5.58 * | |
| 2.7 | 10 | 4.0±0.0 | 1.10±0.66 | 17.8±5.77 | |
Annotate: matched group is compared,
*P＜0.05,
*P＜0.01
Table 11 result as can be seen, sclerotin disappear the pain granule 10% macromolecule right rotary glycoside induced mice microcirculation disturbance is had significant protective effect, blood flow rate is obviously accelerated, and is obviously shortened the normal time of restoration of blood flow, high, middle dosage effect is obvious.
The sclerotin of the present invention particulate laboratory animal internal organs pathologic finding of the pain report that disappears
| Experimental project | Sclerotin disappears the pain granule to the influence of cervical spondylotic radiculopathy rat | ||||
| The specimen source | The SD rat, male | ||||
| The censorship purpose | Observe the sclerotin morphological changes of various tissue components of pain granule that disappear to the rat cervical spondylotic radiculopathy | ||||
| The censorship unit | China Academy of TCM's medical experiment animal center | ||||
| The censorship internal organs | Rat cervical nerves root (model control group, normal control group, sclerotin disappear pain granule high, medium and low three dosage groups) | ||||
| The experiment medicine | Sclerotin disappears bitterly, and granule is provided by dosage form chamber, institute of Chinese materia medica | ||||
| The censorship date | 2003.11.28 | The pathology numbering | 27419-27478 | Reporting date | 2003.12.25 |
1 material and method
1.1 instrument: SAKURA automatic dehydration machine Japan produces; The Leite rotary microtome: Germany makes; SAKURA RSH-100 automatic staining machine: Japan produces; Optical microscope: Japanese Nikon; The automatic microphotograph of OLYMPUS BH-2 system.
1.2 method: rat sacrificed by exsanguination, anatomical isolation are won rat neck 6 nerve rooies, use 10% formaldehyde fixed, the back gradient ethanol dehydration of drawing materials, dimethylbenzene is transparent, and 2 of 3um thickness sheets are cut in the waxdip embedding, does HE, Mallory dyeing respectively, the optical resin gum mounting, om observation, attached photochrome.Carry out statistical procedures with the t check.
2 results
2.1 perusal
The normal control group: rat neck muscular tissue and nerve root color are more shallow, do not see tangible hyperemia, blood stasis and edema, pathological change.
Model control group: part animal cervical region has hyperemia, edema pathological change.
Various dose administration group individual animal cervical region has hyperemia, edema, and is light than model group.
2.2 mirror is observed down
By histology's sxemiquantitative observation caliber, all sections are observed under identical conditions, to causing the get involved upper right corner of nerve root of scorching thing on every side, with optical microscope the variation of different groups are observed.
The normal control group: rat nerve root blood vessel does not see that expansion, hyperemia, nerve fiber do not see tangible edema, inflammatory cell infiltration.
Model control group: the vasodilation of part rat nerve root, mild hyperaemia, the nerve fiber mild swelling, inflammatory cell infiltration is based on lymphocyte.
Disappear pain high, medium and low three the dosage groups of granule and positive control drug individual animal nerve root of sclerotin has mild hyperaemia, edema, inflammatory cell infiltration.
Observation index: adopt nerve root inflammatory and collagen fiber pathological changes comprehensively to judge, carry out statistical procedures with the t check.The histopathology criterion:
The nerve root blood vessel is not seen expansion, hyperemia, nerve fiber, and water breakthrough is not swollen, inflammatory cell infiltration, and structure is normal, and keeping the score is 0;
Nerve fiber Mild edema, a small amount of inflammatory cell infiltration, keeping the score is 1;
Nerve root vasodilation, the nerve fiber Mild edema, inflammatory cell infiltration, keeping the score is 2;
Nerve root vasodilation, hyperemia; The obvious edema of nerve fiber, a large amount of inflammatory cell infiltration, keeping the score is 3;
Nerve root vasodilation, hyperemia; The obvious edema of nerve fiber, fracture, a large amount of inflammatory cell infiltrations, keeping the score is 4.
Table 1 sclerotin disappears the pain granule to the influence of rat radiculitis
| Group | Dosage | Pathological score | |||||||||
| Normal control model control group sclerotin disappear the pain granule | - - 5.4 2.7 1.35 | 0 3 2 2 3 | 0 2 2 2 3 | 0 3 1 3 3 | 0 2 1 2 2 | 0 2 3 3 1 | 0 3 1 2 1 | 0 4 2 1 2 | 0 3 1 1 1 | 0 2 3 2 2 | 0 3 2 1 3 |
Table 2 sclerotin disappears the pain granule to the influence of rat cervical spondylotic radiculopathy
| Form | Dosage (g/mg) | Mus number (only) | The pathological changes integration |
| The model control group sclerotin disappear the pain granule | - 5.4 2.7 1.35 | 10 10 10 10 | 2.7±0.67 1.8±0.79* 1.9±0.74* 2.1±0.88 |
Compare with model control group,
*P＜0.05
*P＜0.01
Table 2 result shows, the vasodilation of model group rat nerve root, hyperemia, the obvious edema of fiber, fracture, necrosis, a large amount of inflammatory cell infiltration.The administration group all has improvement in various degree, and big or middle dosage effect is obvious.
Experimental result
1. to the therapeutical effect of rat cervical spondylosis
1.1 influence to the cervical spondylotic radiculopathy rat
Sclerotin of the present invention disappear the pain granule cervical spondylotic radiculopathy activities in rats is improved significantly, body weight rises appreciably, morphological changes of various tissue components such as vasodilation, fiber edema, inflammatory cell infiltration all obviously alleviate.
1.2 influence to rat spinal cord compressing myelopathy
The sclerotin of the present invention pain granule that disappears can make the rat body weight of spinal compression type cervical spondylosis rise appreciably, and to the spinal nerves cellular swelling, nerve takes off the sheath phenomenon, and a matter microglia hypertrophy all has alleviating in various degree, and high, middle dosage effect is obvious.
2, antiinflammatory action
2.1 influence to the mouse knoting oil dropsy of ear
The sclerotin of the present invention mice ear that pain granule height, middle dosage cause Oleum Tiglii that disappears has stronger inhibitory action.
2.2 to the bullate influence of rat granuloma
The sclerotin of the present invention pain granule institute amount of reagent that disappears all has obvious inhibitory action to cott on pellet-induced granuloma formation, and high, middle dosage effect is remarkable.
3, analgesic activity
Sclerotin of the present invention disappears bitterly, and granule can significantly suppress the mouse writhing generation that acetic acid causes; Obviously reduce subcutaneous injection formalin and cause mice pain reaction integration, compare, significant difference is arranged with matched group.
4, the effect of invigorating blood circulation
4.1 influence to the cervical spondylotic radiculopathy hemorheology of rat
The sclerotin of the present invention pain granule administration group that disappears all has in various degree reduction to whole blood viscosity, and high dose group has the obvious suppression effect.
4.2 to the microcirculatory influence of mice
Sclerotin of the present invention disappears bitterly, and granule has significant protective effect to 10% macromolecule right rotary glycoside induced mice microcirculation disturbance.Blood flow rate is obviously accelerated, and obviously shortened the normal time of restoration of blood flow, high, middle dosage effect is obvious.
Above result shows, the sclerotin of the present invention pain granule that disappears all has the obvious treatment effect to spondylotic radiculopathy and spinal compression type cervical spondylosis, and tangible antiinflammatory is arranged, the effect of easing pain, invigorate blood circulation.
Claims (10)
1. a sclerotin stopping analgesic compositions is characterized in that it is the preparation of being made by the raw material of organizing raw medicinal herbs down: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae and 100-400 weight portion Rhizoma Atractylodis.
2. a sclerotin stopping analgesic compositions is characterized in that it is the preparation of being made by the raw material of organizing raw medicinal herbs down: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae, 100-400 weight portion Rhizoma Atractylodis, 100-400 weight Rhizoma Et Radix Notopterygii and 100-400 weight portion Caulis Spatholobi.
3. a sclerotin stopping analgesic compositions is characterized in that it is the preparation of being made by the raw material of organizing raw medicinal herbs down: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae, 100-400 weight portion Rhizoma Atractylodis, 100-400 weight Rhizoma Et Radix Notopterygii, 100-400 weight portion Flos Carthami and 100-400 weight portion Rhizoma Polygoni Cuspidati.
4. a sclerotin stopping analgesic compositions is characterized in that it is the preparation of being made by the raw material of organizing raw medicinal herbs down: 100-400 weight portion Radix Puerariae, 100-400 weight portion Radix Saposhnikoviae, the 100-400 weight portion Radix Angelicae Dahuricae, 100-400 weight portion Rhizoma Atractylodis, 100-400 weight Rhizoma Et Radix Notopterygii, 100-400 weight portion Flos Carthami, 100-400 weight portion Rhizoma Polygoni Cuspidati, 100-400 weight portion Rhizoma Corydalis and 100-400 weight portion Caulis Spatholobi.
5. according to the sclerotin stopping analgesic compositions of claim 4, it is characterized in that it is the preparation of being made by the raw material of organizing raw medicinal herbs down: 100-200 weight portion Radix Puerariae, 100-200 weight portion Radix Saposhnikoviae, the 100-200 weight portion Radix Angelicae Dahuricae, 100-200 weight portion Rhizoma Atractylodis, 100-200 weight Rhizoma Et Radix Notopterygii, 100-200 weight portion Flos Carthami, 100-200 weight portion Rhizoma Polygoni Cuspidati, 100-200 weight portion Rhizoma Corydalis and 100-200 weight portion Caulis Spatholobi.
6. according to the sclerotin stopping analgesic compositions of claim 4, it is characterized in that it is the preparation of being made by the raw material of organizing raw medicinal herbs down: 100 weight portion Radix Puerariaes, 100 weight portion Radix Saposhnikoviaes, the 100 weight portion Radixs Angelicae Dahuricae, 100 weight portion Rhizoma Atractylodis, 100 weight Rhizoma Et Radix Notopterygiis, 100 weight portion Flos Carthamis, 100 weight portion Rhizoma Polygoni Cuspidati, 100 weight portion Rhizoma Corydalis and 100 weight portion Caulis Spatholobis.
7. according to any one sclerotin stopping analgesic compositions among the claim 1-6, it is characterized in that it is the form of granule.
8. the sclerotin stopping analgesic preparation of compositions method of any one among the claim 1-6 is characterized in that comprising following steps:
1) Rhizoma Atractylodis and/or Radix Saposhnikoviae and/or Rhizoma Polygoni Cuspidati and/or the Radix Angelicae Dahuricae are added the water that 6-12 doubly measures, vapor distillation is collected volatile oil, uses β-CDBao He, obtains beta-CD inclusion;
2) with above-mentioned 1) in medicinal residues add water with Flos Carthami and/or Caulis Spatholobi and decoct, filter filtrate and above-mentioned 1) in medicinal liquid merge, concentrated;
3) Rhizoma Corydalis and/or Radix Puerariae and/or Rhizoma Et Radix Notopterygii add the alcohol reflux of the 60-80% that 6-8 doubly measures, filter, and concentrate;
4) merge 2) and 3) in the concentrated solution of acquisition, further be condensed into thick paste, drying under reduced pressure obtains fine powder, with 1) in the beta-CD inclusion of the volatile oil that obtains mix.
9. the preparation method of claim 8 further comprises the step that medicine is granulated.
10. the sclerotin stopping analgesic compositions of any one is used for the treatment of purposes in the medicament of cervical spondylosis in preparation among the claim 1-6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510011563 CN1289105C (en) | 2005-04-14 | 2005-04-14 | Bone pain dispersing granular composition and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510011563 CN1289105C (en) | 2005-04-14 | 2005-04-14 | Bone pain dispersing granular composition and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686202A CN1686202A (en) | 2005-10-26 |
| CN1289105C true CN1289105C (en) | 2006-12-13 |
Family
ID=35304244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510011563 Expired - Fee Related CN1289105C (en) | 2005-04-14 | 2005-04-14 | Bone pain dispersing granular composition and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1289105C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103349682B (en) * | 2013-07-08 | 2014-10-08 | 王圣会 | Traditional Chinese medicine composition for treating cervical spondylosis |
| CN106074727A (en) * | 2016-06-29 | 2016-11-09 | 甘肃中天金丹药业有限公司 | A kind of sclerotin disappears pain Chinese medicine composition and preparation method thereof |
| CN108014309A (en) * | 2016-10-28 | 2018-05-11 | 徐子正 | A kind of externally applied Chinese medicine formula for treating cervical spondylosis and its application method |
| CN109007830A (en) * | 2018-08-01 | 2018-12-18 | 丽睿客信息科技（北京）有限公司 | A kind of food compositions and its preparation method and application |
-
2005
- 2005-04-14 CN CN 200510011563 patent/CN1289105C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686202A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1228071C (en) | Medicament for treating cervical spondylosis and preparation method thereof | |
| CN101062377A (en) | Adhesive plaster for diminishing inflammation, expelling wind and cold and so on and its preparation method | |
| CN1289105C (en) | Bone pain dispersing granular composition and its preparation method | |
| CN1255154C (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1239193C (en) | Chinese medicine for treating trigeminal neuralgia and its preparation method | |
| CN1111043C (en) | Medicine for protrusion of lumber vertebral disc and its preparation | |
| CN1742993A (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN1519017A (en) | Combination of Chinese traditional medicine for treating menorrhagia as well as pharmaceutics and preparation method | |
| CN1188161C (en) | Medicines for treating cervical vertebra illness | |
| CN1478533A (en) | Chinese Medicine for treating cervieal vertebra disease and its preparation method | |
| CN1276775C (en) | Chinese traditional medicine for treating optical fundus hemorrhage and its preparing process | |
| CN1698713A (en) | Compound Fengshining composition and preparation for treating rheumatic arthralgia | |
| CN1562271A (en) | Medication for treating primary disease of purpura haemorhagica and preparation method | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1190228C (en) | Angong hemostatics | |
| CN1520862A (en) | Prepared traditional Chinese medicine for apoplexy and obstruction of qi in the chest | |
| CN1284589C (en) | Medicine for treating acute brain blood vessel disease and its preparation method | |
| CN1772136A (en) | A kind of pharmaceutical composition and preparation method for treating tendon soft tissue injury and osteoarthropathy | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1853679A (en) | Medicinal composition for treating cervical spondylosis and preparation thereof | |
| CN1679679A (en) | Chinese medicine composition and preparation thereof | |
| CN1065764C (en) | Quickly-acting antalgesic liniment and its preparing process | |
| CN100335074C (en) | Chinese medicine oral liquid for treating apoplexia | |
| CN1833695A (en) | Tonifying speen and tonifying kidney granular and its prepn. method | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061213 Termination date: 20100414 |